EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

First-Line Pembrolizumab Monotherapy for Advanced Non-Small Cell Lung Cancer: A Multicenter Real-World Study from Vietnam

Thi Huong Pham, Cam Phuong Pham iD, Thi Thu Huong Nguyen, Khanh Toan Nguyen iD

Current Oncology · 14.04.2026 · 33 (4) · 215

DOI: 10.3390/curroncol33040215 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Current Oncology, online erschienen am 14.04.2026. Verfasst von Thi Huong Pham und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Hanoi Medical University, Hanoi 100000, Vietnam. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study aimed to evaluate the effectiveness and safety of first-line pembrolizumab monotherapy in patients with advanced non-small cell lung cancer (NSCLC) in real-world clinical practice in Vietnam.

Methods

We performed a multicenter retrospective cohort study of patients with locally advanced or metastatic NSCLC who received first-line pembrolizumab monotherapy in Vietnam between January 2018 and August 2024. The primary endpoints were progression-free survival (PFS), overall survival (OS), and safety profile.

Results

A total of 73 patients were included, with a median age of 69 years (range, 47–92). Most patients had good performance status (ECOG PS 0–1, 75.3%) and high PD-L1 expression (TPS ≥ 50%, 86.3%). The overall response rate was 60.3%, and the disease control rate was 79.5%. Median PFS was 11.3 months (95% CI, 6.9–15.8), and median OS was 25.4 months (95% CI, 20.8–30.0). Multivariate analysis identified never-smoking status (HR 3.14, 95% CI 1.16–8.50; p = 0.024), squamous histology (HR 4.09, 95% CI 1.18–14.17; p = 0.026), and low PD-L1 expression (TPS 1–49%) (HR 3.67, 95% CI 1.14–11.78; p = 0.029) as independent predictors of inferior overall survival. Immune-related adverse events, including pneumonitis, hepatitis, nephritis, fever, skin reactions, and myositis, were mostly mild and manageable, with grade 3 toxicity occurring in only 4.2% of patients. Better survival was observed in patients with high PD-L1 expression and non-squamous histology. However, the association with non-squamous histology should be interpreted with caution due to the very small number of squamous cases.

Conclusions

First-line pembrolizumab monotherapy demonstrated favorable effectiveness and acceptable safety in patients with advanced NSCLC in real-world clinical practice in Vietnam. Clinical outcomes were particularly favorable in patients with high PD-L1 expression, non-squamous histology, and a history of smoking. Nevertheless, the survival benefit associated with non-squamous histology should be interpreted cautiously, given the limited number of patients with squamous histology. These findings support the use of pembrolizumab monotherapy in selected patient populations within resource-limited settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalCarcinoma, Non-Small-Cell LungLung NeoplasmsAgedAged, 80 and overFemaleHumansMaleMiddle AgedRetrospective StudiesVietnam

Stichwörter der Autor:innen

Vietnamadvanced stagenon-small cell lung cancerpembrolizumab monotherapy

Substanzen

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunologicalpembrolizumab

Autor:innen und Institutionen

  • Department of Oncology, Hanoi Medical University, Hanoi 100000, Vietnam.
  • Nghe An Oncology Hospital, Nghe An 43000, Vietnam.
  • Nuclear Medicine and Oncology Center, Bach Mai Hospital, Hanoi 100000, Vietnam.
  • Nuclear Medicine Department, Hanoi Medical University, Hanoi 100000, Vietnam.
  • Oncology and Nuclear Medicine Department, University of Medicine and Pharmacy, Vietnam National University, Hanoi 100000, Vietnam.
  • Vietnam National Cancer Hospital, Hanoi 100000, Vietnam.

ORCID-Profile: Cam Phuong Pham, Khanh Toan Nguyen

Zitieren

APA

Pham, T. H., Pham, C. P., Nguyen, T. T. H., & Nguyen, K. T. (2026). First-Line Pembrolizumab Monotherapy for Advanced Non-Small Cell Lung Cancer: A Multicenter Real-World Study from Vietnam. Current Oncology, 33(4), 215. https://doi.org/10.3390/curroncol33040215

Vancouver

Pham TH, Pham CP, Nguyen TTH, Nguyen KT. First-Line Pembrolizumab Monotherapy for Advanced Non-Small Cell Lung Cancer: A Multicenter Real-World Study from Vietnam. Current Oncology. 2026;33(4):215. doi:10.3390/curroncol33040215

BibTeX
@article{Pham2026,
  author = {Pham, Thi Huong and Pham, Cam Phuong and Nguyen, Thi Thu Huong and Nguyen, Khanh Toan},
  title = {First-Line Pembrolizumab Monotherapy for Advanced Non-Small Cell Lung Cancer: A Multicenter Real-World Study from Vietnam},
  journal = {Current Oncology},
  year = {2026},
  volume = {33},
  number = {4},
  pages = {215},
  doi = {10.3390/curroncol33040215}
}
Kostenlos starten →